{"database": "openregs", "table": "documents", "rows": [["FDA-2003-N-0196-0003", "FDA", "FDA-2003-N-0196", "Reference 5  FDA's Evaluation and Comments on the TEA for Encacamene Division of OTC Drug Products Memorandum to Dockets Management, July 14, 2003 re Public Admlnistratlve File for Over-the-Counter Drug Products; Safety and Efficacy, Volume No. 352-01 - Background", "Supporting & Related Material", "BKG-Background Material", "2003-07-30T04:00:00Z", 2003, 7, null, null, "2014-06-09T20:52:46Z", null, 0, 0, "090000648048b554"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "primary_key_values": ["FDA-2003-N-0196-0003"], "units": {}, "query_ms": 0.49992301501333714, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}